Search
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedIt was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop. … In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS].
Categories: Vitamin ESynonyms: VITAMIN E POLYETHYLENE GLYCOL SUCCINATE, VITAMIN E POLYETHYLENE GLYCOL 1000 SUCCINATECefixime
go.drugbank.com/drugs/DB00671ApprovedInvestigational[L49293] The beta-lactam ring of cefixime inhibits bacterial cell wall synthesis by binding to the penicillin-binding proteins which will then result in lysis. … [T894, T322] Additionally, third-generation cephalosporins have been shown to have more stability in the presence of beta-lactamases compared to first- and second-generation cephalosporins.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalProteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022].
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linkerAbiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalIt is used to treat metastatic castration-resistant prostate cancer, hormone-sensitive high-risk metastatic prostate cancer. … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitorsCopper Cu-64
go.drugbank.com/drugs/DB13980ApprovedCopper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approvedCephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide. … [A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.
Products: CEXGRAM -T, CEPRAX CAPSULAS DE 500 MGGallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigational[A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness. … [A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone.